VILLA GUARDIA (Como), Italy--(BUSINESS WIRE)--Gentium S.p.A. (NASDAQ:GENT) today announced that mechanism of action data on Defibrotide will be presented in a poster entitled “Defibrotide, A DNA-Based Drug, Modulates Immune Functions Of The Endothelium: Impact For Cancer Therapy And Transplantation,” authored by G. Eissner, Ph.D., Vice President, Chief of Biology Research for Gentium; M. Iacobelli, M.D., Vice President, Scientific Director for Gentium; G. Koehl; E. Geissler; R. Andreesen; and E. Holler. The poster will be presented at the Keystone Symposium “Mechanisms Linking Inflammation and Cancer,” held in Santa Fe, N.M., February 10-15, 2007. The poster will be presented in the first Poster Session of the Symposium on Sunday, February 11, from 7:30 p.m. to 10:00 p.m. Mountain time.
